Skip to Main Content

Too many of my Twitter interactions with biotech-loving retail investors are unpleasant. If I write an article raising doubts about a small drugmaker’s clinical trial results, or if I call out misleading statements made by an overly promotional biotech CEO, the responses I receive from people who own the stock generally run the gamut from “f—k you, you clueless a–hole” to “I hope you get cancer and die.”

And sometimes, the replies to my work get really nasty.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment